1xbet 다운로드

• Otsuka and Takeda signed an agreement for 1xbet 다운로드 future co-promotion of sales in Japan of TAK-438, whose New Drug Application was submitted in Japan by Takeda and is currently undergoing regulatory review.
• Otsuka, whose product MUCOSTA^®has a top market share as a gastric mucosal protecting agent, and Takeda, whose product TAKEPRON®(generic name: Lansoprazole) has led 1xbet 다운로드 Japanese PPI market for over 20 years since its launch, will both leverage 1xbet 다운로드ir strengths in 1xbet 다운로드 gastrointestinal 1xbet 다운로드rapeutic area to co-promote TAK-438, thus taking concrete actions to resolve issues encountered in 1xbet 다운로드 treatment of acid-related diseases and fur1xbet 다운로드r contribute to healthcare needs.
• Under 1xbet 다운로드 terms of 1xbet 다운로드 agreement, Otsuka will pay Takeda an up-front payment of 20 billion yen and a milestone payment upon NDA approval, and Otsuka will receive a percentage of 1xbet 다운로드 sales (based on certain conditions specified in 1xbet 다운로드 contract) from Takeda.

Tokyo and Osaka, Japan, March 27, 2014 - Otsuka Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Taro Iwamoto; "Otsuka") and Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; President and CEO: Yasuchika Hasegawa; "Takeda") announced today that 1xbet 다운로드 two firms have entered into a co-promotion agreement in Japan for TAK-438 (generic name: Vonoprazan Fumarate), a drug discovered by Takeda for 1xbet 다운로드 treatment of acid-related diseases.

Proton pump inhibitors (PPIs) are currently widely prescribed as first-line 1xbet 다운로드rapy for 1xbet 다운로드 treatment of acid-related diseases in Japan. However, PPIs do not always provide sufficient 1xbet 다운로드rapeutic efficacy, and 1xbet 다운로드 acid secretion inhibitory effects of PPIs may differ among individuals, because of 1xbet 다운로드 protein CYP2C19 which has gene polymorphisms that are involved in metabolism. TAK-438 inhibits proton pumps without 1xbet 다운로드 need for activation by acid, and 1xbet 다운로드 compound is distributed at high concentrations into 1xbet 다운로드 stomach, 1xbet 다운로드 target organ, 1xbet 다운로드reby exerting a nearly maximum inhibitory effect from 1xbet 다운로드 first dose and remaining effective for 24 hours. Unlike PPIs, TAK-438 is not primarily metabolized by CYP2C19 (which has gene polymorphisms). Since TAK-438 is stable in acid and its immediate-release formulation is available without requiring an optimized formulation design (e.g., enteric-coating), 1xbet 다운로드 onset of efficacy does not significantly differ among treated patients. With 1xbet 다운로드se advantages, TAK-438 is expected to become a new 1xbet 다운로드rapeutic agent that resolves issues with current treatments for acid-related diseases.

Two of Otsuka's products have enabled Otsuka to establish a strong presence in 1xbet 다운로드 gastrointestinal 1xbet 다운로드rapeutic area: MUCOSTA, which has a top market share as a gastric mucosal protecting agent, and UBT which is a diagnostic drug for helicobacter pylori infections. Otsuka will co-promote TAK-438, if approved, in cooperation with Takeda, whose product TAKEPRON has led 1xbet 다운로드 Japanese PPI market for over 20 years since its launch. This co-promotion agreement will position 1xbet 다운로드 two companies to offer new treatment options to healthcare professionals working with acid-related diseases, and assist 1xbet 다운로드m in determining 1xbet 다운로드 presence of helicobacter pylori and evaluating 1xbet 다운로드 most suitable 1xbet 다운로드rapy for its eradication.

Otsuka's President and Representative Director, Taro Iwamoto, said, "We are very enthusiastic about entering this collaboration in Japan with Takeda, which has a leadership position in 1xbet 다운로드 gastrointestinal 1xbet 다운로드rapy area. Toge1xbet 다운로드r we have 1xbet 다운로드 opportunity to bring to market an innovative new medicine that is hypo1xbet 다운로드sized to significantly change 1xbet 다운로드 way in which acid-related disorders can be treated and 1xbet 다운로드reby improve 1xbet 다운로드 QOL of many patients."

"TAK-438 offers a new 1xbet 다운로드rapy option for acid-related diseases that require strong acid secretion inhibitory effects," Takeda's President and CEO, Yasuchika Hasegawa said. "I am pleased that we have been able to sign a co-promotion agreement with 1xbet 다운로드 most suitable partner. Takeda will take every possible step in order to meet 1xbet 다운로드 diverse needs of patients and healthcare professionals. "

About 1xbet 다운로드 co-promotion agreement

1xbet 다운로드 details of this agreement are as below:

• Takeda will receive from Otsuka an up-front payment of 20 billion yen and a milestone payment upon regulatory approval.
• Otsuka will receive from Takeda a percentage of 1xbet 다운로드 sales (based on conditions specified in 1xbet 다운로드 contract).
• Japan will be 1xbet 다운로드 area of promotion.
• Fur1xbet 다운로드r details will not be disclosed.

About TAK-438 (generic name: Vonoprazan Fumarate)

TAK-438, discovered by Takeda, belongs to a new class of acid secretion inhibitors called potassium-competitive acid blockers (P-CAB). It competitively inhibits 1xbet 다운로드 binding of potassium ion to H+, K+-ATPase (proton pump) in 1xbet 다운로드 final step of gastric acid secretion in gastric parietal cells. TAK-438 has strong and sustained acid secretion inhibitory effects and shows efficacy from 1xbet 다운로드 early stages of dosing. Phase III trials have been conducted in Japan on indications including gastric ulcer, duodenal ulcer, erosive esophagitis and H.pylori eradication. Based on results obtained from 1xbet 다운로드se trials, Takeda submitted a New Drug Application in Japan in February 2014.